Concentrations of Receptor for Advanced Glycation End Products, VEGF and CML in Plasma, Follicular Fluid, and Peritoneal Fluid in Women With and Without Endometriosis

The etiology and pathogenesis of endometriosis is largely unknown. It has been reported that advanced glycation end products—receptor for advanced glycation end products regulation relates to oxidative stress, inflammatory reaction, apoptosis, and angiogenesis through vascular endothelial growth factor activation. The purpose of this study was to examine whether advanced glycation end products—receptor for advanced glycation end products regulation contributes to the pathogenesis of endometriosis. Plasma, follicular, and peritoneal fluid samples were collected from women with or without endometriosis, and soluble receptor for advanced glycation end products, vascular endothelial growth factor and carboxymethyl lysine levels were measured by enzyme-linked immunosorbent assay. Vascular endothelial growth factor and soluble receptor for advanced glycation end products concentrations were similar in plasma; however, their concentrations in follicular fluid were significantly increased in endometriosis patients (soluble receptor for advanced glycation end products was 132 + 31 pg/mg of protein vs. 105 + 27 pg/mg; vascular endothelial growth factor was 70 + 3 pg/mg vs. 49 + 18 pg/mg, expressed as the mean + standard deviation). Increased soluble receptor for advanced glycation end products and vascular endothelial growth factor levels in a local environment suggest that the advanced glycation end products—receptor for advanced glycation end products may contribute to the pathogenesis of endometriosis. Similar content being viewed by others

Olive DL, Schwartz LB Endometriosis. N Engl J Med. 1993;328:1759–1769. Practice Committee of American Society for Reproductive Medicine. Endometriosis and infertility. Fertil Steril. 2004;81:1441–1446. Starzinski-Powitz A., Gaetje R., Baumann R., et al. Tracing cellar and molecular mechanismas involoved in endometriosis. Human Reprod.Update. 1998;4:724–729. Jones RK, Searle RF, Bulmer JN Apoptosis and Bcl-2 expression in normal human endometrium, endometriosis and adenomyosis. Hum Reprod. 1998;13:3496–3502. Wieser F., Vigne JL, Ryan I., Hornung D., Djalali S., Taylor RN Sulindac suppresses nuclear factor-kappaB activation and RANTES gene and protein expression in endometrial stromal cells from women with endometriosis. J Clin Endocrinol Metab. 2005;90:6441–6447. Martinez S., Garrido N., Pellicer A., et al. Serum interleukin-6 levels are elevated in women with minimal-mild endometriosis. Human Reprod. 2007;22:836–842. Cataldegirmen G., Zeng S., Emond JC, et al. RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med. 2005;201:473–484. Boulanger E., Grossin N., Wautier MP, Taamma R., Wautier JL Mesothelial RAGE activation by AGEs enhances VEGF release and potentiates capillary tube formation. Kidney Int. 2007;71:126–133. Ma W., Lee SE, Guo J., Qu W., Hudson BI, Schmidt AM, Barile GR RAGE ligand upregulation of VEGF secretion in ARPE-19 cells. Invest Ophthalmol Vis Sci. 2007;48:1355–1361. Pullerits R., Bokarewa M., Dahlberg L., Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther. 2005;7:817–824. Vignola S., Picco P., Falcini F., Sabatini F., Buoncompagni A., Gattorno M. Serum and synovial fluid concentration of vascular endothelial growth factor in juvenile idiopathic arthritides. Rheumatology (Oxford). 2002;41:691–696. Stewart C., Cha S., Caudle RM, Berg K., Katz J. Decreased levels of soluble receptor for advanced glycation end products in patients with primary Sjögren’s syndrome. Rheumatol Int. 2008;28:771–776. Nothnick WB Treating endometriosis as an autoimmune disease. Fertil Steril. 2001;76:223–231. Gleicher N., el-Roeiy A., Confino E., Friberg J. Is endometriosis an autoimmune disease? Obstet Gynecol. 1987;70:115–122. Nakamura K., Yamagishi SI, Matsui T., Adachi H., Takeuchi M., Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin Exp Med. 2007;7:188–190. Tesarova P., Kalousova M., Jachymova M., Mestek O., Petruzelka L., Zima T. Receptor for advanced glycation end products (RAGE)-soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest. 2007;25:720–725. Bopp C., Hofer S., Weigand MA, et al. sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res. 2008;147:79–83. McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update. 2000;6:45–55. Kalu E., Sumar N., Bansal A., et al. Cytokine profiles in serum and peritoneal fluid from infertile women with and without endometriosis. J Obstet Gynaecol Res. 2007;33:490–495. Donnez J., Smoes P., Gillerot S., Casanas-Roux F., Nisolle M. Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod. 1998;13:1686–1690. Garrido N., Albert C., Pellicer A., et al. Expression, production, and secretion of vascular endothelial growth factor and interleukin-6 by granulosa cells is comparable in women with and without endometriosis. Fertil Steril. 2001;76:568–575. Na YJ, Yang SH, Lee KS, et al. Effects of peritoneal fluid from endometriosis patients on the release of vascular endothelial growth factor by neutrophils and monocytes. Hum Reprod. 2006;21:1846–1955. Kilic S., Evsen M., Batioglu S., et al. Follicular fluid vascular endothelial growth factor and tumour necrosis factor alpha concentrations in patients with endometriosis undergoing ICSI. Reprod Biomed Online. 2007;15:316–320. Pupo-Nogueira A., de Oliveira RM, Petta CA, Podgaec S., Dias JA Jr, Abrao MS Vascular endothelial growth factor concentrations in the serum and peritoneal fluid of women with endometriosis. Int J Gynaecol Obstet. 2007;99:33–37. Pellicer A., Albert C., Mercader A., Bonilla-Musoles F., Remohí J., Simón C. The follicular and endocrine environment in women with endometriosis: local and systemic cytokine production. Fertil Steril. 1998;70:425–431. Gagné D., Pagé M., Robitaille G., Hugo P., Gosselin D. Levels of vascular endothelial growth factor (VEGF) in serum of patients with endometriosis. Hum Reprod. 2003;18:1674–1680. Matalliotakis IM, Goumenou AG, Vassiliadis S., et al. Serum concentrations of growth factors in women with and without endometriosis: the action of anti-endometriosis medicines. Int Immunopharmacol. 2003;3:81–89. Kalousová M., Jáchymová M., Zima T., et al. Receptor for advanced glycation end products-soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant. 2007;22:2020–2026. KAO LC, Germeyer A., Giudice LC, et al. Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility. Endocrinology. 2003;144:2870–2881. Author information Authors and Affiliations Corresponding author Additional information The study was supported by the Ministry of Health, Labour and Welfare research expense, Policy consignment 17–6, Japan. Rights and permissions About this article Cite this article Fujii, E.Y., Nakayama, M. & Nakagawa, A. Concentrations of Receptor for Advanced Glycation End Products, VEGF and CML in Plasma, Follicular Fluid, and Peritoneal Fluid in Women With and Without Endometriosis. Reprod. Sci. 15, 1066–1074 (2008). https://doi.org/10.1177/1933719108323445 Published: Issue date: DOI: https://doi.org/10.1177/1933719108323445